LGD 6972

Drug Profile

LGD 6972

Alternative Names: Compound G; Compound H; Cpd G; Cpd H; GCGR Antagonist Program - Ligand Pharmaceuticals; LGD-6972; LGD-6972 sodium salt; MB-11262

Latest Information Update: 15 Sep 2016

Price : $50

At a glance

  • Originator Metabasis Therapeutics
  • Developer Ligand Pharmaceuticals
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Glucagon receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 01 Sep 2016 Phase-II clinical trials in Type-2 diabetes mellitus (Treatment-experienced) in USA (PO) (NCT02851849)
  • 15 Aug 2016 Pooled pharmacodynamics data from two phase I trials in Type-2 Diabetes mellitus released by Ligand Pharmaceuticals
  • 17 May 2016 Ligand Pharmaceuticals completes a phase I trial in Type-2 Diabetes mellitus (In volunteers) in USA (NCT02672839)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top